Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Research Reports

Negative perceptions about emergency contraception are likely to hamper the sales of “morning after” pills in the future. Despite the high accessibility of emergency contraceptive pills, followed by rising awareness of highly-effective birth control methods, incidences of unwanted or mistimed pregnancies persist.

Moreover, high risk of morbidity and mortality associated with these pregnancies is disintegrating the fabric of urban cultures.

Strategizing The Moves For The Next Decade? See Through Sample Of Emergency Contraceptive Pills Market Report! https://www.persistencemarketresearch.com/samples/18343

Company Profile

  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG, HRA Pharma
  • Piramal Enterprises Limited
  • Mankind Pharma Ltd.
  • Richter Gedeon Nyrt
  • Lupin Limited
  • Cooper Pharma
  • Pfizer Inc.
  • Zhejiang Xianju Pharmaceutical Co.
  • Others

While unprotected sex continues to be a matter of mutual consent, obstetricians advise couples to opt for emergency contraception, particularly in healthcare settings with lack of accessibility to proper & safe abortion. Since unprotected sex also increases the risks of sexually transmitted infections, the ineffectiveness of emergency contraceptive pills in protection from venereal diseases continues to be a concern for manufacturers.

Sales of emergency contraceptive pills are also being adversely impacted by unresolved side effects of emergency contraception – which include time constraint for intake, heavy vomiting, muscle spasms, and feeling nauseous.

According to Persistence Market Research’s newly-published study, the global sales of emergency contraceptive pills are expected to dwindle in the next five years. By the end of 2022, the global market for emergency contraceptive pills will have reached a value of just over US$ 1,230 Mn. During the forecast period, 2017-2022, the global emergency contraceptive pill market is anticipated to exhibit sluggish growth and reflect less than 3% CAGR.

Get a Customized Scope to Match Your Need Ask an Expert- sales@persistencemarketresearch.com

Combination Pills showcase promising growth potential

The report segments the global market for emergency contraceptive pills on the basis of products, among which combination pills are expected to dominate the market revenues.

In the foreseeable future, combination pills will witness relatively higher sales in the global market, primarily due to their health benefits in reducing risk of ectopic pregnancy. In 2017, nearly two-fifth of revenues procured in the global emergency contraceptive pills market will be contributed by global sales of combination pills.

On the contrary, use of estrogen pills for emergency contraception will lose traction. Over the forecast period, estrogen pills as a product in the global emergency contraceptive pills market will exhibit revenue growth at just 1.5% CAGR.

Demand for progesterone pills is also expected to drop, particularly owing to their side effects which include joint pain, hot flashes, and diarrhea.

How About Obtaining Insights About The Region To Enter Concerning The Emergency Contraceptive Pills Market? Press The “Purchase Now” Button To Have Our Emergency Contraceptive Pills Market Report! https://www.persistencemarketresearch.com/checkout/18343

Online Traders will reflect low sales growth

Key findings from the report indicate drug stores and hospital pharmacies as the two largest sales channels for emergency contraceptive pills. In 2017, sales of emergency contraceptive pills through these channels is expected to account for collective global revenue share of nearly 70%.

Online sales of emergency contraceptive pills will incur a considerable decline, and procure not more than US$ 160 Mn in global revenues by the end of 2022.

The report also identifies North America as the largest market for emergency contraceptive pills. The International Consortium for Emergency Contraception is based in the US and serves the mission of expanding access to safe and appropriate use of emergency contraception products.

Read More Trending “PMR Exclusive Article”-

Ineffective Esophageal Motility Treatment MarketIneffective Esophageal Motility Treatment Market is Segmented by Devices such as Reflux Management Systems, Endoscopic Pain Modulators, Endostaplers Radiofrequency (RF) Ablation Devices, Myotomy Devices having Drugs such as H2 Receptor Antagonists, Antacids Proton Pump Inhibitors, Dopamine Antagonists, Prokinetic Agents, Calcium Channel Blockers

About Us: – Persistence Market Research

Contact us:

Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

 

Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts